Clinical diagnosis of AD remains a challenge since there are no validated tests for an affirmative diagnosis and moreover several conditions can mimic it and their accuracy is suboptimal. Positron Emission Tomography (PET), is a modality for early detection of AD. 18F-Florbetapir is a novel PET tracer for amyloid brain pathology and AD imaging, while PET images with 18F-fluorodeoxyglucose (FDG) for cerebral glucose metabolism can provide complementary information to amyloid plaque imaging for diagnosis of AD. Aim of our study was to evaluate: (a) to witch degree amyloid imaging data could alter our clinical and diagnostic approach to AD, (b) the concordance degree with FDG PET imaging.
18F-Florbetapir and 18F-FDG PET studies in the diagnostic evaluation of Alzheimer's disease
GRAGNANIELLO, Daniela;CITTANTI, Corrado;MILANI, Paola;TUGNOLI, Valeria
2016
Abstract
Clinical diagnosis of AD remains a challenge since there are no validated tests for an affirmative diagnosis and moreover several conditions can mimic it and their accuracy is suboptimal. Positron Emission Tomography (PET), is a modality for early detection of AD. 18F-Florbetapir is a novel PET tracer for amyloid brain pathology and AD imaging, while PET images with 18F-fluorodeoxyglucose (FDG) for cerebral glucose metabolism can provide complementary information to amyloid plaque imaging for diagnosis of AD. Aim of our study was to evaluate: (a) to witch degree amyloid imaging data could alter our clinical and diagnostic approach to AD, (b) the concordance degree with FDG PET imaging.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
